Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410588 | 0.82 | GAA (0.42) | GAASMN1; SMN2 | |
| SCHEMBL2607885 | 0.74 | CYP4A11 (0.51) | CYP4F2CYP4A11PTGS2PPARARAB9A | |
| SCHEMBL12410458 | 0.73 | NPC1 (0.40) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11955603 | 0.72 | CYP4F2 (0.41) | CYP4F2CYP4A11PTGS2PPARARAB9A | |
| SCHEMBL29046738 | 0.71 | PPARA (0.53) | CYP4F2CYP4A11PTGS2PPARASMN1; SMN2 | |
| SCHEMBL15459743 | 0.70 | PPARA (0.56) | CYP4F2CYP4A11PTGS2PPARATHRB | |
| SCHEMBL12419012 | 0.69 | CYP4F2 (0.41) | CYP4F2CYP4A11PTGS2PPARARAB9A | |
| SCHEMBL6662199 | 0.69 | PTGS2 (0.65) | CYP4F2CYP4A11PTGS2PPARARAB9A | |
| Methyl Alcohol SCHEMBL7111417 | 0.67 | PTGS2 (0.63) | CYP4F2CYP4A11PTGS2PPARARAB9A | |
| SCHEMBL342562 | 0.66 | THRB (0.72) | CYP4F2CYP4A11PTGS2PPARATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8449872-B2 | Polymer conjugates of nesiritide peptides | NEKTAR THERAPEUTICS (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NGLY1, IAPP, NPSR1 | CYP4F2 3802/4885CYP4A11 1856/4885PTGS2 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.